- Find a clinical trial
- XL092-311
NETS
XL092-311
A phase 2/3, multicentre, randomized open-label study of zanzalintinib VS everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumours.
Trial overview
Medical Oncology
NETS
Gastrointestinal (GI)
II
Registration number: NCT06943755
St Leonards (North Shore Health Hub)
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
Thank you for submitting.
Thank you for submitting.
We will be in touch within 24 hours
Form submission error
An unexpected error has occurred.
You will need to complete the form again, sorry for the inconvenience.
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.